Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 139

1.

Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion.

Hoellen F, Waldmann A, Banz-Jansen C, Rody A, Heide M, Köster F, Ribbat-Idel J, Thorns C, Gebhard M, Oberländer M, Habermann JK, Thill M.

Oncol Lett. 2016 Oct;12(4):2351-2356.

2.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016.

Thill M, Liedtke C; AGO Breast Committee..

Breast Care (Basel). 2016 Jun;11(3):216-22. doi: 10.1159/000447030. No abstract available.

3.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016.

Liedtke C, Thill M; AGO Breast Committee..

Breast Care (Basel). 2016 Jun;11(3):204-14. doi: 10.1159/000446941. No abstract available.

4.

Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.

Thill M, Pisa G, Isbary G.

Geburtshilfe Frauenheilkd. 2016 May;76(5):551-556.

5.

Targeted Therapy in HER2-Positive Breast Cancer.

Thill M, Kraft C, Friedrich M.

Oncol Res Treat. 2016;39(5):295-302. doi: 10.1159/000446038.

PMID:
27173915
6.

Somatic tinnitus prevalence and treatment with tinnitus retraining therapy.

Ostermann K, Lurquin P, Horoi M, Cotton P, Hervé V, Thill MP.

B-ENT. 2016;12(1):59-65.

PMID:
27097395
7.

ABC3 Consensus: Assessment by a German Group of Experts.

Thomssen C, Augustin D, Ettl J, Haidinger R, Lück HJ, Lüftner D, Marmé F, Marschner N, Müller L, Overkamp F, Ruckhäberle E, Thill M, Untch M, Wuerstlein R, Harbeck N.

Breast Care (Basel). 2016 Feb;11(1):61-70. doi: 10.1159/000443515.

8.

ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015.

Untch M, Augustin D, Ettl J, Haidinger R, Harbeck N, Lück HJ, Lüftner D, Marmé F, Müller L, Overkamp F, Ruckhäberle E, Thill M, Thomssen C, Wuerstlein R, Marschner N.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):156-163. Review.

9.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium..

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6.

PMID:
26590673
10.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.

Liedtke C, Thill M, Hanf V, Schuütz F; AGO Breast Committee..

Breast Care (Basel). 2015 Jul;10(3):199-205. doi: 10.1159/000431248. No abstract available.

11.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015.

Hanf V, Schütz F, Liedtke C, Thill M; AGO Breast Committee..

Breast Care (Basel). 2015 Jul;10(3):189-97. doi: 10.1159/000431346. No abstract available.

12.

The Prevention of Positioning Injuries during Gynecologic Operations. Guideline of DGGG (S1-Level, AWMF Registry No. 015/077, February 2015).

Fleisch MC, Bremerich D, Schulte-Mattler W, Tannen A, Teichmann AT, Bader W, Balzer K, Renner SP, Römer T, Roth S, Schütz F, Thill M, Tinneberg H, Zarras K.

Geburtshilfe Frauenheilkd. 2015 Aug;75(8):792-807.

13.

Aromatase Inhibitors in the Prevention of Breast Cancer.

Stickeler E, Fehm T, Schütz F, Thill M.

Breast Care (Basel). 2015 Apr;10(2):141-2. doi: 10.1159/000430877. No abstract available.

14.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators..

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8.

15.
16.

Vitamin D inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression.

Thill M, Woeste A, Reichert K, Fischer D, Rody A, Friedrich M, Köster F.

Anticancer Res. 2015 Feb;35(2):1197-203.

PMID:
25667511
17.

Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors.

Thill M, Reichert K, Woeste A, Polack S, Fischer D, Hoellen F, Rody A, Friedrich M, Köster F.

Anticancer Res. 2015 Feb;35(2):1189-95.

PMID:
25667510
18.

New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.

Thill M.

Expert Rev Anticancer Ther. 2015 Mar;15(3):331-8. doi: 10.1586/14737140.2015.993318. Review.

PMID:
25539719
19.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.

Hanf V, Schütz F, Liedtke C, Thill M; AGO Breast Committee..

Breast Care (Basel). 2014 Jul;9(3):202-9. doi: 10.1159/000363551. No abstract available.

20.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.

Liedtke C, Thill M, Hanf V, Schütz F; AGO Breast Committee..

Breast Care (Basel). 2014 Jul;9(3):189-200. doi: 10.1159/000363591. No abstract available.

Supplemental Content

Loading ...
Support Center